Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Surrozen, Inc. filings on SEC EDGAR ↗
Surrozen, Inc. entered into an underwriting agreement for a public offering of 1,894,540 shares of common stock at a price of $31.67 per share. The company expects to receive gross proceeds of approximately $60 million from the offering, which is scheduled to close on November 16, 2026.
Value
$60M
Counterparty
Morgan Stanley & Co. LLC, Guggenheim Securities, LLC and Cantor Fitzgerald & Co.
Surrozen, Inc. reported a net loss of $207.1 million for the nine months ended September 30, 2026, significantly higher than the $58.9 million loss in the prior year period, primarily driven by a $111.5 million loss on the change in fair value of tranche liabilities. Total revenue for the nine-month period was $10.0 million, derived from collaboration and license revenue, while operating expenses increased to $48.5 million due to higher research and development costs.
Surrozen is transitioning to a clinical-stage company with a dual-mechanism approach for retinal diseases, backed by a $95 million financing tranche triggered by IND opening.
Surrozen reported Q3 2026 financial results and announced the expansion of its Phase 2a DUET study for SZN-8141 from 60 to 150 patients. The company strengthened its balance sheet in October 2026 by closing a $95.1 million private placement tranche and raising $29.8 million via its ATM program, extending its cash runway into 2029.
Term
Q3 2026
“We have made important progress advancing Surrozen into its next stage of development, with the first patient dosed in the SZN-8141 DUET study and plans to significantly expand Phase 2a enrollment from approximately 60 to 150 patients. The additional capital raised in October positions us to generate a more robust clinical dataset across a broader DME population, while maintaining anticipated cash runway into 2029.”
Craig Parker, President and Chief Executive Officer
Surrozen is transitioning to a clinical-stage company with a $15 billion market opportunity, leveraging a $95 million financing tranche triggered by its IND filing for lead candidate SCN-8141 in diabetic macular edema.
Surrozen completed the second and final tranche of a private placement, raising approximately $95.1 million in gross proceeds. The closing was triggered by the achievement of a milestone involving FDA clearance of the IND application for SZN-8141. The funding is expected to provide a cash runway into 2029 to advance the company's ophthalmology pipeline through clinical milestones.
Value
$95.1M
“The completion of this financing marks an important milestone for Surrozen, significantly strengthening our balance sheet and providing the resources to advance our ophthalmology pipeline through multiple important clinical milestones.”
Craig Parker, President and Chief Executive Officer
“With expected cash runway into 2029, we are well positioned to advance SZN-8141 into the DUET Phase 1b/2a study and initiate clinical development of SZN-8143, while maintaining a disciplined approach to capital allocation.”
Craig Parker, President and Chief Executive Officer